Project Grant HT94252510190

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $391,553 to Viewpoint Molecular Targeting, Inc. to develop an image-guided, targeted alpha-particle therapy for the treatment of metastatic high-grade serous ovarian carcinoma (HGSOC). The goal is to commercialize a new alpha-particle radiotherapy approach that combines Viewpoint's proprietary radionuclide chelation and production technologies with an innovative "pretargeting"...

This $399,478 Project Grant was awarded by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395) to Trio Pharmaceuticals, Inc. for developing a novel targeted antibody therapy called TRIO-628 to treat ovarian cancer. The key objective is to improve ovarian cancer treatment by generating more immunogenic tumors through the selective elimination of both cancer cells and myeloid-derived suppressor cells (MDSCs), which contribute to an...

This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $131,600 in funding to Harvard College President & Fellows Of, through its Harvard T.H. Chan School of Public Health Division, to conduct research aimed at understanding and exploiting apoptotic dysregulation in ovarian cancer. The key objectives of the research project are to: 1) Ascertain apoptotic regulation and pro-survival protein dependence in pre-malignant and...

This Project Grant award from the National Institutes of Health National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop a nanoparticle formulation of the mediator kinase inhibitor SNX631-6 for the treatment of peritoneal ovarian cancer metastases. The key objectives are to optimize the nanoparticle formulation for improved pharmacokinetics and tumor targeting upon intraperitoneal administration, evaluate the safety and efficacy...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively targets and delivers cytotoxic agents to cancer cells with hyperactive membrane-anchored serine proteases. The goal is to create a novel, tumor-targeted therapeutic strategy to treat metastatic and recurrent solid tumors, including ovarian, lung, and colon cancers. The research aims to...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $503,685 to Virginia Commonwealth University (VCU) to conduct research on targeted degradation of the epidermal growth factor receptor (EGFR) and HER2 proteins in non-small cell lung cancer (NSCLC). The key objectives are to: 1) assess a novel agent called PEPDG278D for inhibiting oncogenic signaling and achieving antitumor effects in NSCLC cells and tumors expressing wild-type EGFR,...

This Project Grant award of $695,797 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports a multi-disciplinary research program focused on discovering new tumor antigens and T-cell receptors (TCRs) for the treatment of platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The award aims to leverage innovative multi-omic technologies, including long-read RNA sequencing and immunopeptidomics, to uncover cancer-specific protein isoforms that can...

This $267,527 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center aims to investigate mechanisms of resistance in SMARCA4-mutant lung cancer to KRAS G12C inhibitors, and evaluate the potential of SMARCA2-targeting compounds to overcome this resistance. The key products and services to be delivered under this 2-year grant include: Mechanistic studies to understand how SMARCA4 mutations confer...

This Project Grant award of $241,944 from the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) will support research to investigate the efficacy and mechanism of combining two natural product compounds - didesmethylrocaglamide (DDR) and phyllanthusmin34 (PHY34) - for treating high grade serous ovarian cancer (HGSOC). The University of Illinois will conduct in vivo studies to evaluate the combinatorial effects of DDR and PHY34 on tumor...

The federal Project Grant award R41CA291316 for $349,808, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports the development of Oncurie Inc.'s novel targeted radiopharmaceutical platform for imaging and therapy of ovarian cancer. The key features of the platform include a folate receptor-binding moiety to target the receptor's overexpression in ovarian cancer, and Oncurie's proprietary radionuclide-binding domain. During the Phase I...